Trial reportDrug design, development and therapy2026
Anti-Vascular Endothelial Growth Factor Combined with Dexamethasone Implant Therapy for Macular Edema: A Randomized Controlled Trial.
Trial report in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To compare the efficacy and safety of intravitreal conbercept monotherapy versus conbercept combined with dexamethasone implant in eyes with macular edema (ME). Methods: Patients diagnosed with ME secondary to diabetic retinopathy or retinal vein occlusion were enrolled and randomized 1:1 to the combined or monotherapy group. In initial 12 weeks, the combined group received 1 loading dose of conbercept concomitantly with dexamethasone implant (DEX), while the monotherapy group received 3 monthly loading doses of conbercept. Following initial phases, all patients received intravitreal injections of conbercept on demand, assessed every 4 weeks over a 48-week follow-up period. The primary outcome measure was changes in best-corrected visual acuity (BCVA). Secondary outcome measures encompassed changes in optical coherence tomography (OCT) biomarkers and the total number of injections administered. Clinical safety was evaluated based on the incidence and severity of adverse events. Results: 70 patients (70 eyes) were randomized to monotherapy (n=36) or combination therapy (n=34). Mean (SD) baseline BCVA and CMT were 44.60 (7.34) letters and 555.55 (150.87) μm in monotherapy group; 37.61 (13.47) letters and 581.80 (145.87) μm in combined group. The combined group showed greater BCVA improvement by week 8 and CMT reduction at weeks 4 and 8, and OCT biomarkers also improved more substantially during the first 12 weeks. The combination therapy required significantly fewer injections (P < 0.001) overall but a higher incidence of ocular hypertension. Outcomes of BCVA and CMT correlated with Hard Exudate (HE). Conclusion: Conbercept combined with DEX is an efficient and safe treatment for ME by providing accelerated visual and anatomical improvements in short term and maintaining similar long-term efficacy with fewer injections compared to conbercept monotherapy. OCT biomarkers display prognostic value. HE is associated with poor visual prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.